N/A
N=56
Novel Medication as a Potential Smoking Cessation Aid
Tobacco Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT02265367 ↗Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Percent of Days of Confirmed Abstinence (Out of 5 Maximum) — 46.9; 42.0 percentage of days non-smoking
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Levomilnacipran (Drug); Placebo (Drug)
- Age
- Adult · 25+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- May 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Days of Confirmed Abstinence (Out of 5 Maximum) |
46.9; 42.0 | — |
Summary
The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
Eligibility Criteria
Inclusion Criteria
- Be between 25 years old and 55 years old
- Smoke a minimum number of cigarettes per day
- Indicate motivation to quit smoking
Exclusion Criteria
- Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication
- Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran
- Are pregnant or breast feeding
The investigators will evaluate if there are other reasons why someone may not be eligible to participate
Data sourced from ClinicalTrials.gov (NCT02265367). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.